AI-generated from publicly available materials.RNAV8 Bio has secured funding from ARPA-H to advance the PROPEL initiative, aimed at enhancing RNA medicines through programmable control mechanisms.
RNAV8 Bio, known for its AI-driven approach to mRNA design, is collaborating with prestigious labs at Harvard and MIT under a $4.4 million ARPA-H pilot program. The PROPEL initiative seeks to leverage RNA’s natural folding behavior to create a tunable control layer for RNA therapeutics. This effort addresses the existing challenges in predicting the relationship between RNA sequences and their functional outputs, as highlighted by RNAV8's CEO, Devan Shah.
The project's innovative angle lies in its focus on RNA's untranslated regions (UTRs), which can be engineered to respond to small molecules. This capability allows for adjustable protein expression without altering the genome, marking a shift from traditional genetic therapies that typically induce permanent DNA changes. The team aims to map how these UTRs function across various cell types, potentially unlocking new therapeutic applications.
Ultimately, the PROPEL initiative aspires to generate a comprehensive resource, including a catalog of human RNA sequences and their responses to small molecules. This foundational work could significantly advance the field of RNA medicine, making it more versatile and applicable across diverse diseases.